Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0SZ6E
|
||||
Former ID |
DIB005388
|
||||
Drug Name |
YN-968D1
|
||||
Synonyms |
Apatinib; Apatinib mesylate; VEGF receptor inhibitor (cancer), Advenchen; VEGFR2 receptor inhibitor (cancer), LSK/ Jiangsu Henrui/ Bukwang
|
||||
Drug Type |
Small molecular drug
|
||||
Company |
Advenchen Laboratories LLC
|
||||
Structure |
Download2D MOL |
||||
Formula |
C24H23N5O
|
||||
InChI |
InChI=1S/C24H23N5O/c1-17-10-14-26-15-21(17)29-22-20(5-4-13-27-22)23(30)28-19-8-6-18(7-9-19)24(16-25)11-2-3-12-24/h4-10,13-15H,2-3,11-12H2,1H3,(H,27,29)(H,28,30)
|
||||
InChIKey |
MGZNERAVOCFMCU-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Inhibitor | [531412] | |
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY network | |||||
References | |||||
Ref 525168 | ClinicalTrials.gov (NCT02426034) Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer. U.S. National Institutes of Health. | ||||
Ref 542631 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7648). | ||||
Ref 549965 | Clinical pipeline report, company report or official report of LSK BioPharma. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.